GlassScriptPhysician profile
Marla M Troyer
NPI 1114482676
$6,326.14
in general payments reported to CMS, 2019-2025
41 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,814 · 2022: $2,009 · 2023: $1,633 · 2024: $461 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.07 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $814.89 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $681.09 | 2021-2023 | Farxiga |
| Insulet Corporation | $629.91 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $442.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.02 | 2021-2024 | Jardiance, Ofev |
| Abbvie INC. | $362.41 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $357.64 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $283.25 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $276.10 | 2021-2023 | Gvoke Hypopen |
| Medtronic, INC. | $181.33 | 2022-2025 | Inpen Smart Insulin Delivery System |
| Esperion Therapeutics, INC. | $177.97 | 2021-2023 | Nexletol |
| Mylan Specialty L.P. | $177.45 | 2022-2023 | Yupelri |
| Abbott Laboratories | $174.24 | 2023-2024 | Freestyle Libre 3, Freestyle Insulinx |
| Pfizer INC. | $165.88 | 2022-2025 | |
| Dexcom, INC. | $139.59 | 2021-2024 | Dexcom G6 Transmitter |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $103.31 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $98.07 | 2021-2023 | |
| Amarin Pharma, INC. | $90.59 | 2021-2022 | |
| Amgen INC. | $89.29 | 2022-2025 | Repatha, Evenity, Prolia |
| Ibsa Pharma INC. | $68.42 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $64.62 | 2021-2023 | Unithroid |
| Boston Scientific Corporation | $57.36 | 2023-2024 | Watchman Flx, Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.94 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $43.93 | 2021-2023 | Isturisa, Signifor Lar |
| Amryt Pharma Holdings LTD | $41.82 | 2021-2023 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $41.57 | 2021 | |
| Tandem Diabetes Care, INC. | $35.65 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $28.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.27 | 2022-2023 | Xifaxan |
| Sequel Med Tech, LLC | $27.86 | 2025 | Twiist |
| Glaxosmithkline, LLC. | $26.24 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $24.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.48 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $19.67 | 2022 | |
| Optos, INC. | $19.60 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.50 | 2023 | Rexulti |
| Beta Bionics, INC. | $17.24 | 2024 | Ilet Bionic Pancreas |
| Antares Pharma, INC. | $16.70 | 2023 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $15.07 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $14.01 | 2023 | Tymlos |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Troyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.